317 related articles for article (PubMed ID: 29130344)
1. Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
Rapoport BL; Jordan K; Weinstein C
Future Oncol; 2018 Jan; 14(1):77-92. PubMed ID: 29130344
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
3. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
4. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.
Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Vallejos W; Liang LW; Noga SJ; Rapoport BL
Ann Oncol; 2016 Jan; 27(1):172-8. PubMed ID: 26449391
[TBL] [Abstract][Full Text] [Related]
5. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
6. HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis.
Navari RM
Future Oncol; 2019 Jan; 15(3):241-255. PubMed ID: 30304952
[TBL] [Abstract][Full Text] [Related]
7. Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV).
Choi MR; Jiles C; Seibel NL
J Pediatr Hematol Oncol; 2010 Oct; 32(7):e268-71. PubMed ID: 20736848
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
9. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.
Aapro M; Carides A; Rapoport BL; Schmoll HJ; Zhang L; Warr D
Oncologist; 2015 Apr; 20(4):450-8. PubMed ID: 25795636
[TBL] [Abstract][Full Text] [Related]
10. Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting.
Van Belle SJ; Cocquyt V
Expert Opin Pharmacother; 2008 Dec; 9(18):3261-70. PubMed ID: 19040346
[TBL] [Abstract][Full Text] [Related]
11. The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy.
Navari RM
Expert Opin Drug Saf; 2019 Dec; 18(12):1127-1132. PubMed ID: 31622113
[No Abstract] [Full Text] [Related]
12. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
Bosnjak SM; Dimitrijevic J; Djordjevic F
Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies.
Cabanillas Stanchi KM; Ebinger M; Hartmann U; Queudeville M; Feucht J; Ost M; Koch MS; Malaval C; Mezger M; Schober S; Weber S; Michaelis S; Lange V; Lang P; Handgretinger R; Döring M
Drug Des Devel Ther; 2019; 13():3439-3451. PubMed ID: 31686784
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients.
Mora J; Valero M; DiCristina C; Jin M; Chain A; Bickham K
Pediatr Blood Cancer; 2019 Jun; 66(6):e27690. PubMed ID: 30900392
[TBL] [Abstract][Full Text] [Related]
17. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.
dos Santos LV; Souza FH; Brunetto AT; Sasse AD; da Silveira Nogueira Lima JP
J Natl Cancer Inst; 2012 Sep; 104(17):1280-92. PubMed ID: 22911671
[TBL] [Abstract][Full Text] [Related]
18. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
19. IV aprepitant (Cinvanti) for chemotherapy-induced nausea and vomiting.
Med Lett Drugs Ther; 2018 Dec; 60(1561):e200-e201. PubMed ID: 30653479
[No Abstract] [Full Text] [Related]
20. Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials.
Navari RM
Cancer Invest; 2004; 22(4):569-76. PubMed ID: 15565815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
